Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
In this episode, Spencer and Karl discuss a recent study on semaglutide for treating metabolic dysfunction associated steatotic liver disease (MASH). They explore the implications of the study, the Essence trial, and the potential of new treatments for obesity and liver health. The conversation also touches on the importance of early treatment and the need for more accessible medication options.